UBS AM’s Solid Biosciences SLDB Stock Holding History

UBS AM’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$21.3K	Hold	2,133	–	–	﹤0.01%	3117
2026 Q1	$15.4K	Buy	2,133 +1,634	+327%	+$10.5K	﹤0.01%	3198
2025 Q4	$2.81K	Buy	+499	New	+$2.7K	﹤0.01%	3080

Other funds holding SLDB

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS AM's SLDB Position: Q2 2026 in Review

UBS AM held its Solid Biosciences (SLDB) position steady in Q2 2026 at 2,133 shares worth $21.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3117.

UBS AM first reported a position in SLDB in Q4 2025 and has held it in 3 quarters since. 157 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

UBS AM held 2,133 shares of Solid Biosciences worth $21.3K as of Q2 2026.
UBS AM left its Solid Biosciences share count unchanged in Q2 2026.
Solid Biosciences made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #3117 holding.
UBS AM first reported a position in Solid Biosciences in Q4 2025 and has held it in 3 quarters since.
157 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.